The comprehensive immunomonitoring analysis performed in this study provides relevant insight for the rational design of future therapeutic approaches in mRCC and other malignancies such as neuroendocrine tumors, in which mTOR inhibitors are also used as anti-cancer therapeutics. Here, MTOR is linked to cancer.